Mirtazapin Viatris (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Viatris, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It works by modulating neurotransmitter activity and is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support.

Mirtazapine, marketed as Mirtazapin Viatris, acts on noradrenergic and serotonergic pathways to treat depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood in adult patients. - Depressive episodes with anxiety features: alleviates anxiety and promotes better sleep quality. - Treatment‑resistant depression (adjunct): may enhance therapeutic response when combined with other antidepressants.

Mirtazapin Viatris may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (rash, swelling, difficulty breathing) - Low white blood cell count (agranulocytosis) - Mood changes including suicidal thoughts

Before initiating therapy, clinicians should consider several safety factors.

- Assess psychiatric history: monitor for worsening depression or emergence of suicidal thoughts. - Evaluate hepatic or renal impairment: adjust therapy based on clinical judgment. - Review concomitant medications: avoid use with monoamine oxidase inhibitors. - Caution in elderly patients: increased risk of sedation and falls. - Store at ambient temperature (below 25 °C): keep in original packaging, protect from moisture and light.

Mirtazapin Viatris can interact with other medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; a washout period is required. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CNS depressants (alcohol, benzodiazepines): additive sedation. - CYP2D6 substrates (e.g., codeine): altered metabolism may affect efficacy. - Anticholinergic agents: may exacerbate dry mouth and constipation.